Mitoxantrone in Patients with Acute Leukemia in Relapse

Paolo Alberto Paciucci, Takao Ohnuma, Janet Cuttner, James F. Holland

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydro-chloride). The drug was given as a rapid i.v. infusion for 5 days, and doses were escalated from 8 mg/sq m daily for 5 days to 20 mg/sq m daily for 5 days. Five of 12 patients with acute lymphoblastic leukemia were induced into complete remission; one patient was induced into complete remission twice. The marrow response lasted from 3 to 50+ weeks. Among 12 patents with acute myelogenous leukemia, there was one complete and one partial remission, with response duration lasting 8 and 2 weeks. One patient with chronic myelogenous leukemia in blastic crisis also had a partial remission lasting 17 weeks. Remissions occurred at doses ranging from 8 to 14 mg/sq m daily for 5 days. All responders had been treated previously with anthracydines. Drug-induced side effects included dose-limiting oral mucositis, sporadic nausea and vomiting, and transient elevations of the hepatic enzymes. Approximately one-third of the patients had septic complications during the myelosuppres-sive phase following treatment. We believe that mitoxantrone has definite utility in the treatment of acute leukemia in relapse.

Original languageEnglish
Pages (from-to)3919-3922
Number of pages4
JournalCancer Research
Issue number8
StatePublished - 1 Aug 1983


Dive into the research topics of 'Mitoxantrone in Patients with Acute Leukemia in Relapse'. Together they form a unique fingerprint.

Cite this